STOCK TITAN

Castle Biosciences - CSTL STOCK NEWS

Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.

Castle Biosciences, Inc. (CSTL) delivers innovative diagnostic solutions that transform cancer care through genomic insights. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in precision oncology diagnostics.

Access authoritative information about CSTL’s latest developments, including new test validations, clinical study results, and strategic partnerships. Our curated collection features earnings reports, regulatory milestones, and research breakthroughs across key focus areas like melanoma diagnostics and pharmacogenomics.

Stay informed about critical updates including:
- FDA-cleared test announcements
- Peer-reviewed study publications
- Financial performance reports
- Collaborative oncology initiatives
- Expanded clinical utility data

Bookmark this page for streamlined access to Castle Biosciences’ verified news. Check regularly for updates that impact diagnostic practices and investment considerations in the genomic testing sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
-
Rhea-AI Summary
Castle Biosciences to present new data on gene expression profile tests for cutaneous squamous cell carcinoma and melanoma at AHNS conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
52.86%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.47%
Tags
none
Rhea-AI Summary
Castle Biosciences grants restricted stock units (RSUs) to 68 employees as an inducement for employment. The RSUs will vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
none
-
Rhea-AI Summary
Castle Biosciences announces new data demonstrating the ability of the DecisionDx-SCC test to identify high-risk tumors in patients with low-risk staging for cutaneous squamous cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.48%
Tags
none
-
Rhea-AI Summary
Castle Biosciences to present new data on DecisionDx-Melanoma and DecisionDx-UM at ASCO Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
none
-
Rhea-AI Summary
Castle Biosciences continues its collaboration with The Sun Bus and The Skin Cancer Foundation to support skin cancer prevention, research, education, and advocacy during Skin Cancer Awareness Month. The company emphasizes the importance of prevention, early detection, and optimized treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.31%
Tags
none
Castle Biosciences

Nasdaq:CSTL

CSTL Rankings

CSTL Stock Data

620.45M
28.04M
3.35%
93.97%
6.48%
Diagnostics & Research
Services-medical Laboratories
Link
United States
FRIENDSWOOD